AU2016291708B2 - Plinabulin compositions - Google Patents

Plinabulin compositions Download PDF

Info

Publication number
AU2016291708B2
AU2016291708B2 AU2016291708A AU2016291708A AU2016291708B2 AU 2016291708 B2 AU2016291708 B2 AU 2016291708B2 AU 2016291708 A AU2016291708 A AU 2016291708A AU 2016291708 A AU2016291708 A AU 2016291708A AU 2016291708 B2 AU2016291708 B2 AU 2016291708B2
Authority
AU
Australia
Prior art keywords
plinabulin
compositions
plinabulin compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016291708A
Other languages
English (en)
Other versions
AU2016291708A1 (en
Inventor
Lan Huang
Aniruddh SINGH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BeyondSpring Pharmaceuticals Inc
Original Assignee
BeyondSpring Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57757489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2016291708(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by BeyondSpring Pharmaceuticals Inc filed Critical BeyondSpring Pharmaceuticals Inc
Publication of AU2016291708A1 publication Critical patent/AU2016291708A1/en
Application granted granted Critical
Publication of AU2016291708B2 publication Critical patent/AU2016291708B2/en
Priority to AU2021201784A priority Critical patent/AU2021201784B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/004—Fractional crystallisation; Fractionating or rectifying columns
    • B01D9/0045—Washing of crystals, e.g. in wash columns
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • B01D9/0054—Use of anti-solvent
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/0063—Control or regulation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D2009/0086—Processes or apparatus therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2016291708A 2015-07-13 2016-07-11 Plinabulin compositions Active AU2016291708B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021201784A AU2021201784B2 (en) 2015-07-13 2021-03-22 Plinabulin compositions

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562191990P 2015-07-13 2015-07-13
US62/191,990 2015-07-13
PCT/US2016/041773 WO2017011399A1 (en) 2015-07-13 2016-07-11 Plinabulin compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021201784A Division AU2021201784B2 (en) 2015-07-13 2021-03-22 Plinabulin compositions

Publications (2)

Publication Number Publication Date
AU2016291708A1 AU2016291708A1 (en) 2018-02-01
AU2016291708B2 true AU2016291708B2 (en) 2020-12-24

Family

ID=57757489

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016291708A Active AU2016291708B2 (en) 2015-07-13 2016-07-11 Plinabulin compositions
AU2021201784A Active AU2021201784B2 (en) 2015-07-13 2021-03-22 Plinabulin compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021201784A Active AU2021201784B2 (en) 2015-07-13 2021-03-22 Plinabulin compositions

Country Status (21)

Country Link
US (5) US10155748B2 (enExample)
EP (2) EP3334726B1 (enExample)
JP (2) JP6969848B2 (enExample)
KR (1) KR102680823B1 (enExample)
CN (3) CN108026075B (enExample)
AU (2) AU2016291708B2 (enExample)
BR (1) BR112018000229A2 (enExample)
CA (1) CA2991059C (enExample)
CL (1) CL2018000098A1 (enExample)
CO (1) CO2018000350A2 (enExample)
DK (1) DK3334726T3 (enExample)
EC (1) ECSP18010481A (enExample)
ES (1) ES2910035T3 (enExample)
IL (1) IL256559B2 (enExample)
MX (1) MX376122B (enExample)
MY (1) MY181892A (enExample)
NZ (1) NZ778077A (enExample)
PE (1) PE20180528A1 (enExample)
PH (1) PH12018500071A1 (enExample)
SG (1) SG10202108194XA (enExample)
WO (1) WO2017011399A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016229295B2 (en) 2015-03-06 2021-11-04 Beyondspring Pharmaceuticals, Inc. Method of treating a brain tumor
SG10202008673WA (en) 2015-03-06 2020-10-29 Beyondspring Pharmaceuticals Inc Method of treating cancer associated with a ras mutation
US10155748B2 (en) 2015-07-13 2018-12-18 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
JP2019511565A (ja) 2016-02-08 2019-04-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド ツカレゾールまたはそのアナログを含む組成物
AU2017278245B2 (en) 2016-06-06 2022-09-15 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing neutropenia
CN109563079B (zh) 2016-08-12 2021-10-26 深圳华大海洋科技有限公司 脱氢苯基阿夕斯丁类化合物的多晶型及其制备纯化方法和应用
CN107011331A (zh) * 2016-08-12 2017-08-04 青岛海洋生物医药研究院股份有限公司 脱氢苯基阿夕斯丁类化合物的多晶型及其制备方法
EP3565812B1 (en) 2017-01-06 2023-12-27 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
KR20240110997A (ko) 2017-02-01 2024-07-16 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증의 감소 방법
US11434225B2 (en) 2017-08-03 2022-09-06 Pliva Hrvatska D.O.O. Salts and solid state forms of plinabulin
EP3743074A4 (en) 2018-01-24 2021-12-15 Beyondspring Pharmaceuticals Inc. COMPOSITION AND METHOD FOR REDUCING THROMBOCYTOPENIA BY THE ADMINISTRATION OF PLINABULINE
WO2022216908A1 (en) 2021-04-09 2022-10-13 Beyondspring Pharmaceuticals, Inc. Therapeutic compositions and methods for treating tumors
EP4475811A4 (en) * 2022-02-10 2026-01-21 Beyondspring Pharmaceuticals Inc STABLE PLINABULIN FORMULATIONS AND THEIR METHODS OF PREPARATION AND USE
CN117860672A (zh) * 2022-10-11 2024-04-12 大连万春布林医药有限公司 一种普那布林胶束组合物及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070078138A1 (en) * 2002-08-02 2007-04-05 Michael Palladino Analogs of dehydrophenylahistins and their therapeutic use

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS509164A (enExample) 1973-05-11 1975-01-30
GR76950B (enExample) 1980-12-18 1984-09-04 Wellcome Found
AU576322B2 (en) 1983-07-22 1988-08-25 Ici Australia Limited Alpha-substituted-alpha-cyanomethyl alcohols
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
JPH05255106A (ja) 1990-10-31 1993-10-05 Toray Ind Inc 血小板減少症治療剤
JPH059164A (ja) 1991-07-02 1993-01-19 Sumitomo Chem Co Ltd 光学活性マンデロニトリル誘導体の製造方法
GB9217331D0 (en) 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds
ES2096215T3 (es) 1992-10-01 1997-03-01 Wellcome Found Tucaresol como agente inmunopotenciador.
US6096786A (en) 1992-10-01 2000-08-01 Glaxo Wellcome Inc. Immunopotentiatory agent and physiologically acceptable salts thereof
US5872151A (en) 1992-10-01 1999-02-16 Glaxo Wellcome Inc. Immunopotentiatory agents and physiologically acceptable salts thereof
ES2224200T3 (es) 1992-11-27 2005-03-01 Mayne Pharma (Usa) Inc. Composicion inyectable estable de paclitaxel.
JPH0725858A (ja) 1993-07-13 1995-01-27 Otsuka Pharmaceut Co Ltd ピペラジン誘導体
US5958980A (en) 1993-08-26 1999-09-28 Glaxo Wellcome, Inc. Immunopotentiatory agent and physiologically acceptable salts thereof
IL110787A0 (en) 1993-08-27 1994-11-11 Sandoz Ag Biodegradable polymer, its preparation and pharmaceutical composition containing it
GB9402807D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9402809D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9426224D0 (en) 1994-12-23 1995-02-22 Xenova Ltd Pharmaceutical compounds
US5891877A (en) 1995-02-14 1999-04-06 Xenova Limited Pharmaceutical compounds
US5874443A (en) 1995-10-19 1999-02-23 Trega Biosciences, Inc. Isoquinoline derivatives and isoquinoline combinatorial libraries
US5886210A (en) 1996-08-22 1999-03-23 Rohm And Haas Company Method for preparing aromatic compounds
JP3131574B2 (ja) 1996-09-04 2001-02-05 新日本製鐵株式会社 新規抗腫瘍物質、該物質を製造するための微生物及び方法、並びに該物質を有効成分とする細胞周期阻害剤及び抗腫瘍剤
US5939098A (en) 1996-09-19 1999-08-17 Schering Corporation Cancer treatment with temozolomide
US5922683A (en) 1997-05-29 1999-07-13 Abbott Laboratories Multicyclic erythromycin derivatives
ES2352739T3 (es) 1997-11-21 2011-02-22 Purdue Neuroscience Company 2-aminoacetamidas sustituidas y el uso de las mismas.
CN1173946C (zh) 1998-01-29 2004-11-03 阿温蒂斯药物公司 制备n-[(脂族或芳族)羰基]-2-氨基乙酰胺化合物和环化化合物的方法
US7141603B2 (en) 1999-02-19 2006-11-28 The Regents Of The University California Antitumor agents
US6069146A (en) 1998-03-25 2000-05-30 The Regents Of The University Of California Halimide, a cytotoxic marine natural product, and derivatives thereof
EP1069111A4 (en) 1998-03-26 2001-06-06 Shionogi & Co INDOLE DERIVATIVES EXER ANT ANTIVIRAL ACTIVITY
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
FR2784988B1 (fr) 1998-10-23 2002-09-20 Adir Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7026322B2 (en) 1998-11-12 2006-04-11 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
US6358957B1 (en) 1998-11-12 2002-03-19 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
PT1210428E (pt) 1999-08-23 2015-07-21 Genetics Inst Llc Pd-1, um recetor para b7-4 e suas utilizações
MXPA02001878A (es) 1999-08-23 2003-08-20 Dana Farber Cancer Inst Inc Moleculas b7-4 novedosas y usos de las mismas.
EP1234031B2 (en) 1999-11-30 2021-11-24 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
CA2403790C (en) 2000-01-18 2011-09-27 Nereus Pharmaceuticals, Inc. A cell division inhibitor and a production method thereof
EP1265840A2 (en) 2000-03-17 2002-12-18 Corixa Corporation Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
JP5101781B2 (ja) 2000-05-09 2012-12-19 アンギオアールエックス コーポレイション ピペラジンジオン化合物
JP2004518731A (ja) 2000-12-28 2004-06-24 ニューロクライン バイオサイエンシーズ， インコーポレイテッド 三環式ｃｒｆレセプターアンタゴニスト
US20030082140A1 (en) 2001-08-20 2003-05-01 Fisher Paul B. Combinatorial methods for inducing cancer cell death
WO2003074550A2 (en) 2002-03-01 2003-09-12 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
RS96304A (sr) 2002-05-17 2006-10-27 Aventis Pharma S.A. Primena docetaksel/doksorubicin/ ciklofosfamida u adjuvantnoj terapiji raka dojke i jajnika
US7012100B1 (en) 2002-06-04 2006-03-14 Avolix Pharmaceuticals, Inc. Cell migration inhibiting compositions and methods and compositions for treating cancer
US7935704B2 (en) 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
DE60316688T2 (de) 2002-08-02 2008-07-17 Nereus Pharmaceuticals, Inc., San Diego Dehydrophenylahistine und analoge davon sowie ein verfahren zur herstellung von dehydrophenylahistinen und analogen davon
CN101633655B (zh) * 2002-08-02 2014-04-30 大连万春药业有限公司 脱氢苯基阿夕斯丁及其类似物以及脱氢苯基阿夕斯丁及其类似物的合成
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
WO2005077940A1 (en) * 2004-02-04 2005-08-25 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
CN1934101B (zh) * 2004-02-04 2011-10-12 尼瑞斯药品公司 脱氢苯基阿夕斯丁及其类似物以及脱氢苯基阿夕斯丁及其类似物的合成
PL1740593T3 (pl) 2004-04-19 2016-09-30 Sposoby wytwarzania wodorosiarczanu klopidogrelu w formie polimorficznej I
DE202004018940U1 (de) 2004-12-07 2006-04-13 Asf Verwaltungs Gmbh Druckverschluß, Druckverschlußband und wiederverschließbarer Beutel
JP4559240B2 (ja) 2005-01-13 2010-10-06 株式会社エヌ・ティ・ティ・ドコモ 移動通信システム、無線基地局、無線回線制御局及び電力制御方法
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
CA2612241C (en) 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
WO2007035841A1 (en) 2005-09-21 2007-03-29 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
AU2007207465B2 (en) 2006-01-18 2012-12-06 Merck Patent Gmbh Specific therapy using integrin ligands for treating cancer
WO2007113648A2 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
US8129527B2 (en) * 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
AU2008216669B2 (en) 2007-02-15 2013-12-12 Mannkind Corporation A method for enhancing T cell response
JP5641927B2 (ja) 2007-04-13 2014-12-17 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー Ｓｐａｒｃ及びその使用方法
US20090170837A1 (en) 2007-08-17 2009-07-02 Thallion Pharmaceuticals Inc. Methods for treating ras driven cancer in a subject
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
KR20100100949A (ko) 2008-01-08 2010-09-15 브리스톨-마이어스 스큅 컴퍼니 증식성 질환의 치료를 위한 튜불린 조정제와 항-ｃｔｌａ４ 항체의 조합물
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
UY31952A (es) 2008-07-02 2010-01-29 Astrazeneca Ab 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
EP4209510B1 (en) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
MX2011007583A (es) 2009-01-16 2011-12-14 Teva Pharma Nuevas formulaciones estables de proteina de fusion recombinante de albumina humana-factor humano de estimulacion de colonias de granulocitos.
WO2010114922A1 (en) 2009-03-31 2010-10-07 Agios Pharmaceuticals, Inc. Methods of treating cancer having an aberrant egfr or kras genotype
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
EP2464218B1 (en) 2009-08-10 2015-05-27 Board of Regents, The University of Texas System Treatment of brain metastases with inhibitors of endothelin receptors in combination with a cytotoxic chemotherapy agent
CA2939165A1 (en) 2009-09-15 2011-03-24 Cerulean Pharma Inc. A cdp-camptothecin conjugate, particle or composition and uses thereof
WO2011050344A2 (en) 2009-10-23 2011-04-28 Mannkind Corporation Cancer immunotherapy and method of treatment
NO2504364T3 (enExample) 2009-11-24 2018-01-06
CN101766815B (zh) 2009-12-31 2012-04-25 胡松华 紫杉醇及多西紫杉醇的用途
EP2542699A4 (en) 2010-03-03 2013-10-02 Targeted Molecular Diagnostics Llc METHODS FOR DETERMINING REACTIVITY TO A MEDICINE BASED ON DETERMINATION OF RAS MUTATION AND / OR RAS AMPLIFICATION
US20130064831A1 (en) 2010-05-17 2013-03-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
US20130131018A1 (en) 2010-06-04 2013-05-23 Exonhit S.A. Substituted isoquinolines and their use as tubulin polymerization inhibitors
JP2012033526A (ja) 2010-07-28 2012-02-16 Fuji Electric Co Ltd 薄膜太陽電池およびその製造方法
WO2012035436A1 (en) * 2010-09-15 2012-03-22 Tokyo University Of Pharmacy And Life Sciences Plinabulin prodrug analogs and therapeutic uses thereof
WO2012074904A2 (en) 2010-11-29 2012-06-07 Precision Therapeutics, Inc. Methods and systems for evaluating the sensitivity or resistance of tumor specimens to chemotherapeutic agents
TWI386203B (zh) 2011-01-07 2013-02-21 Univ China Medical 治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用
SI2699264T1 (en) 2011-04-20 2018-08-31 Medimmune Llc Antibodies and other molecules that bind b7-h1 and pd-1
WO2013078537A1 (en) 2011-11-28 2013-06-06 National Research Council Of Canada Paclitaxel response markers for cancer
US20150004175A1 (en) 2011-12-13 2015-01-01 Yale University Compositions and Methods for Reducing CTL Exhaustion
BR112014028094B1 (pt) 2012-05-09 2022-03-03 Cantex Pharmaceuticals, Inc Uso de um heparinoide interagindo com fator de plaqueta 4
AU2013204313C1 (en) 2012-06-01 2016-04-07 Bionomics Limited Combination Therapy
US10034939B2 (en) 2012-10-26 2018-07-31 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
LT2958943T (lt) 2013-02-20 2020-01-27 The Trustees Of The University Of Pennsylvania Vėžio gydymas, naudojant humanizuotą anti-egfrviii chimerinio antigeno receptorių
WO2014160183A1 (en) 2013-03-13 2014-10-02 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity
US10809323B2 (en) 2013-04-24 2020-10-20 Tel Hashomer Medical Research Infrastructure And Services Ltd. Magnetic resonance maps for analyzing tissue
CN105658206A (zh) 2013-06-03 2016-06-08 诺华股份有限公司 抗pd-l1抗体与mek抑制剂和/或braf抑制剂的组合
EP3076972B1 (en) 2013-10-11 2021-10-06 BeyondSpring, Inc. Cancer treatment with combination of plinabulin and taxane
IL292510A (en) 2013-11-05 2022-06-01 Cognate Bioservices Inc Combinations of checkpoint inhibitors and therapeutics to treat cancer
EP3066215B1 (en) 2013-11-06 2019-04-24 The United States of America, represented by the Secretary, Department of Health and Human Services Method for subtyping lymphoma types by means of expression profiling
CN104796448B (zh) 2014-01-22 2019-02-12 腾讯科技（深圳）有限公司 网络系统的数据处理方法和装置
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
US10392444B2 (en) 2014-08-08 2019-08-27 Oncoquest, Inc. Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer
KR20240110996A (ko) 2015-02-12 2024-07-16 비욘드스프링 파마수티컬스, 인코포레이티드. 면역 관문 저해제와 조합한 플리나불린의 용도
AU2016229295B2 (en) 2015-03-06 2021-11-04 Beyondspring Pharmaceuticals, Inc. Method of treating a brain tumor
SG10202008673WA (en) 2015-03-06 2020-10-29 Beyondspring Pharmaceuticals Inc Method of treating cancer associated with a ras mutation
WO2016165007A1 (en) 2015-04-17 2016-10-20 The University Of British Columbia Inhibitors of estrogen receptor alpha and their use as therapeutics for cancer
US10155748B2 (en) 2015-07-13 2018-12-18 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
WO2017062505A1 (en) 2015-10-05 2017-04-13 Cedars-Sinai Medical Center Method of classifying and diagnosing cancer
JP2019511565A (ja) 2016-02-08 2019-04-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド ツカレゾールまたはそのアナログを含む組成物
AU2017278245B2 (en) 2016-06-06 2022-09-15 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing neutropenia
EP3565812B1 (en) 2017-01-06 2023-12-27 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
KR20240110997A (ko) 2017-02-01 2024-07-16 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증의 감소 방법
NZ778329A (en) 2017-03-13 2026-03-27 Beyondspring Pharmaceuticals Inc Compositions of plinabulin and use thereof
EP3743074A4 (en) 2018-01-24 2021-12-15 Beyondspring Pharmaceuticals Inc. COMPOSITION AND METHOD FOR REDUCING THROMBOCYTOPENIA BY THE ADMINISTRATION OF PLINABULINE
CA3089391A1 (en) 2018-02-01 2019-08-08 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing chemotherapy-induced neutropenia via the administration of plinabulin and a g-csf agent
JP7500438B2 (ja) 2018-06-01 2024-06-17 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド Ｅｇｆｒ変異に関連する癌の治療組成物及び治療方法
EP3836930A4 (en) 2018-08-16 2022-05-11 Beyondspring Pharmaceuticals Inc. Method and composition for stimulating immune response

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070078138A1 (en) * 2002-08-02 2007-04-05 Michael Palladino Analogs of dehydrophenylahistins and their therapeutic use

Also Published As

Publication number Publication date
IL256559B1 (en) 2023-03-01
US20200277280A1 (en) 2020-09-03
US12024501B2 (en) 2024-07-02
CN108026075A (zh) 2018-05-11
SG10202108194XA (en) 2021-09-29
US20220169635A1 (en) 2022-06-02
EP3334726A4 (en) 2019-04-17
ECSP18010481A (es) 2018-04-30
IL256559A (en) 2018-02-28
US10155748B2 (en) 2018-12-18
WO2017011399A1 (en) 2017-01-19
US11254657B2 (en) 2022-02-22
CL2018000098A1 (es) 2018-07-20
CN109516981B (zh) 2019-10-22
EP4011878A1 (en) 2022-06-15
KR20180027563A (ko) 2018-03-14
BR112018000229A2 (pt) 2018-09-04
JP2018520178A (ja) 2018-07-26
US20240425485A1 (en) 2024-12-26
NZ739083A (en) 2024-11-29
IL256559B2 (en) 2023-07-01
MY181892A (en) 2021-01-12
JP2021181497A (ja) 2021-11-25
US20190106410A1 (en) 2019-04-11
PE20180528A1 (es) 2018-03-19
EP3334726A1 (en) 2018-06-20
AU2021201784B2 (en) 2022-12-01
CN109516981A (zh) 2019-03-26
CO2018000350A2 (es) 2018-06-12
PH12018500071B1 (en) 2018-07-23
EP3334726B1 (en) 2022-03-16
CN108026075B (zh) 2021-06-29
DK3334726T3 (da) 2022-05-16
US10550104B2 (en) 2020-02-04
US20180194749A1 (en) 2018-07-12
CA2991059A1 (en) 2017-01-19
CA2991059C (en) 2024-01-16
JP6969848B2 (ja) 2021-11-24
MX2018000451A (es) 2018-05-07
CN113735834A (zh) 2021-12-03
NZ778077A (en) 2024-11-29
CN113735834B (zh) 2023-06-13
AU2021201784A1 (en) 2021-04-15
MX376122B (es) 2025-03-07
HK1251559A1 (zh) 2019-02-01
PH12018500071A1 (en) 2018-07-23
AU2016291708A1 (en) 2018-02-01
KR102680823B1 (ko) 2024-07-03
ES2910035T3 (es) 2022-05-11

Similar Documents

Publication Publication Date Title
EP3240555A4 (en) Multi-supplement compositions
EP3322441A4 (en) Vaccine compositions
EP3240416A4 (en) Fungicidal compositions
EP3215173B8 (en) Glycopeptide compositions
EP3040326A4 (en) Halo-olefin composition
IL256559B1 (en) Flinbolin preparations
EP3240556A4 (en) Bacterial compositions
EP3221420A4 (en) Photochromic-electrochromic compositions
EP3373928A4 (en) NEW FORMULATIONS
EP3248475A4 (en) Composition
EP3323837A4 (en) Composition
EP3067338A4 (en) Water-settable composition
EP3277755A4 (en) Algae-blended compositions without plasticizers
EP3265211A4 (en) Nanolaminated 2-2-1 max-phase compositions
EP3288386A4 (en) Anti-phytopathogenic compositions
EP3270888A4 (en) Anti-pathogenic compositions
EP3231430A4 (en) Composition
EP3191110A4 (en) Polygalacturonan rhamnogalacturonan1 (pgrg1) composition
EP3247347A4 (en) Anti-bacterial compositions
EP3265318A4 (en) Primer compositions
EP3265320A4 (en) Primer compositions
EP3125321A4 (en) Organic-semiconductor-film-forming composition
EP3265317A4 (en) Primer compositions
EP3265319A4 (en) Primer compositions
EP3214161A4 (en) Cleaning-agent composition

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)